Negative Air Ion (6) FDA未承認を掲げて販売を続けたElanra USA


この期間のうち、2003年1月23日2006年10月17日には、燦然と輝く「Important FDA Notice: The Elanra porducts are not yet cleared by the FDA for distribution in the United States」が全ページに貼り付けられた記録が残されている。最後の記録はデータ崩壊状態なので確認できないが、おそらくそのままだと思われる。


Rockville, Maryland 20850
Mr. Tracy Campbell
Elanra.com, Inc.
778 Poppy Rd.
San Marcos, CA 92078
7447 East Quien Sabe Way
Scottsdale, AZ 85262
7832 Soaring Eagle Way
Scottsdale, AZ 85262
RE: Elanra Therapeutic Ionizers
Dear Mr. Campbell:

We are writing to you because we are in receipt of information from your firm ’s web site, http://www.elanra.com, that indicates your firm is marketing the above referenced product in the United States for providing "major benefits for asthma, sinus, hay fever, allergies, depression, emphysema, CFS, CS, fibromyalgia, and migraines." Under a United States law, the Federal Food, Drug, and Cosmetic Act (the Act), this product is considered to be a medical device because it is intended for use in the diagnosis or treatment of a medical condition or to affect the structure or function of the body (Section 201(h) of the Act.)

The law requires that the manufacturer or the distributor of medical devices obtain marketing clearance for their products from FDA before they may offer them for sale. This helps protect the public health by ensuring that new medical devices are shown to be both safe and effective or substantially equivalent to other devices already legally marketed in this country.

貴社が「喘息、副鼻洞、花粉症、アレルギー、鬱、気腫、CFS、CS、線維筋痛、片頭痛に主たる効果がある」という上記製品を米国で販売していることを示す、貴社のwebサイト http://www.elanra.com から情報を得たので、我々は本警告を出している。米国の法律「連邦食料医薬品化粧品法」のもとでは、この製品は医学的状態を診断あるいは治療もしくは、身体の構造あるいは機能に影響を及ぼすことを目的として使用されるので、医療機器と考えられる。(Section 201 (h) )


A review of our records has determined that there is no premarket clearance or approval in effect for the device you are offering for sale in this country. The kind of information you need to submit in order to obtain this clearance is described on the agency ’s Internet web site at http://www.fda.gov/cdrh/devadvice/3122.html.

The FDA will evaluate this information and decide whether your product may be legally marketed in this country.

Because your therapeutic ionizer devices do not have marketing clearance or approval from FDA, marketing them in this country is a violation of the law. In legal terms, the product is adulterated under section 501 (f)(l)(B) and misbranded under section 502(o) of the Act. Your product is adulterated under the Act because you did not obtain premarket approval based on information developed by you that shows your device is safe and effective. Your product is misbranded under the Act because you did not submit information that shows your device is substantially equivalent to other devices that are legally marketed.

FDAの記録を調べた結果、貴社が米国で販売している機器について市販前承認がなされていないことが判明した。この承認を受けるために貴社がなすべきことFDAのページ http://www.fda.gov/cdrh/devadvice/3122.html. に記載されている。


貴社の治療用イオン化装置をFDAの市販承認なしに米国で販売することは違法行為である。法律用語では偽和(section 501 (f)(l)(B))であり、偽造(section 502(o))である。貴社の製品は貴社の製品が安全かつ効果があると示す貴社の情報に基づく市販前承認を受けていないので、偽和である。また、貴社の製品が合法的に市販されている他の機器と等価であることを示す情報を提示していないので偽造である。

You should know that this is a serious violation of the law and may result in FDA taking regulatory action without further notice to you. These actions include, but are not limited to, seizing your product inventory, obtaining a court injunction against further marketing of the product, or assessing civil money penalties. Also, other Federal agencies are informed about the warning letters we issue, such as this one, so that they may consider this information when awarding government contracts.

Given the serious nature of these violations of the Act, these therapeutic ionizer devices may be detained without physical examination upon entry into the United States until these violations are corrected.

It is necessary for you to take action on this matter now. Please let this office know in writing within fifteen (15) working days from the date you received this letter, what steps you are taking to correct the problem. We also ask that you explain how you plan to prevent this from happening again. If you need more time, let us know why and when you expect to complete your correction. Please direct your response to:




James W. Eisele
U.S. Food and Drug Administration
CDRH, Office of Compliance
Center for Devices and Radiological Health
2098 Gaither Rd.
Rockville, MD 20850

Finally, you should understand that there are many FDA requirements pertaining to the manufacture and marketing of medical devices. This letter pertains only to the issue of premarket clearance for your device and does not necessarily address other obligations you have under the law. You may obtain general information about all of FDA ’s requirements for manufacturers of medical devices by contacting our Division of Small Manufacturers, International and Consumer Assistance at 1-800-638-2041 or through the Internet at www.fda.gov

If you have more specific questions about how FDA marketing requirements affect your particular device or about the content of this letter, please feel free to contact James Eisele at (301) 594-4659.

Sincerely yours,
Donald Serra for Philip J. Frappaolo
Acting Director
Office of Compliance
Center for Devices and Radiological Health
この警告に対するElanraUSAの反応は、燦然と輝く「Important FDA Notice: The Elanra porducts are not yet cleared by the FDA for distribution in the United States」を表示することだった。そして、ElanraUSAは安全性と効果を示すことなく、2007年に米国から撤退した。

posted by Kumicit at 2010/04/07 07:48 | Comment(0) | TrackBack(0) | Quackery | このブログの読者になる | 更新情報をチェックする



コメント: [必須入力]